Kim Tan is the Chairman of Springhill Management (UK), a fund management company specializing in biotech and social impact investments. He is a partner of a number of social impact funds including Novastar Ventures (Kenya), Inqo Investments (South Africa), and Garden Impact (Singapore). He is the co-founder of the Transformational Business Network and the inventor of sheep monoclonal antibodies. He serves on the advisory boards of J&J Social Ventures and the Centre for Enterprise Markets & Ethics. He is a Pro-Chancellor of the University of Surrey and a Fellow of the Royal Society of Medicine.
Dr. Tan attended several Lyford Cay summits with Sir John Templeton, including the 2004 Lyford Cay Summit on Innovation in Philanthropy and the 2005 Lyford Cay Summit on Entrepreneurial Philanthropy and Enterprise-Based Solutions to Poverty. In addition, he participated in the 2008 Lyford Cay Summit on Free Enterprise, Innovation, and Entrepreneurial Wealth Creation in Africa. He is a Member of the John Templeton Foundation and Templeton World Charity Foundation, and a Steering Committee member of the Templeton Religion Trust.